Arthritis Clinical Trial
Official title:
A Multi-Center Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | October 2024 |
Est. primary completion date | October 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male and female subjects age 18 or older - Clinical diagnosis of gout according to the 2015 ACR/EULAR Gout Classification Criteria: A) For newly presenting subjects: Diagnosis of gout must be confirmed in the target joint as indicated by either the presence of monosodium urate (MSU) crystals by microscopic evaluation of synovial fluid from the target joint or bursa OR by imaging evidence of urate deposition in the target joint or bursa at the Screening/Baseline Visit/Study Day 1, or B) For previously diagnosed subjects: Confirmation of gout diagnosis as per criterion 2a OR history of gout diagnosis per one of the following: a. Documented history of the presence of MSU crystals in synovial fluid from the target joint or bursa ; or b. Historical imaging report of urate deposition in the target joint or bursa in their medical record5; or c. Documented history of 2 or more gout flares in the previous 18 months - Confirmation of a gout flare in the target joint that began within 96 hours prior to the Screening/Baseline Visit - Provide written informed consent and understand and comply with all trial requirements Exclusion Criteria: - Presence of any palpable and visible tophi by physical examination - Has = 4 joints with an acute gout flare at Screening/Baseline - Presence of rheumatoid arthritis or other acute inflammatory arthritis - Evidence/suspicion of infectious/septic arthritis - Clinically significant general pain or non-gout-related joint pain that would interfere with the subject's ability to accurately assess pain in the target joint - Known diagnosis of chronic kidney disease or known history of renal impairment - Positive test for severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection, if tested, within 4 weeks of the Screening/Baseline - Active malignancy or recent malignancy with any systemic anti-cancer treatment - Has a hypersensitivity or allergy to OLT1177® or other drugs in its class - Hypersensitivity or allergy to paracetamol/acetaminophen - Use of any prohibited concomitant medications/therapies over the periods defined in the protocol or planned use of any prohibited concomitant medications/therapies during the Treatment Period (including the use of paracetamol/acetaminophen within 4 hours prior to the Screening/Baseline Visit or other pain medications within 12 hours prior to the Screening/ Baseline Visit - Use of any product containing paracetamol/acetaminophen within 4 hours prior to the Screening/Baseline Visit or planned use during the Treatment Period (with the exception of study-provided Rescue Medication [paracetamol/acetaminophen], which is permitted after completion of the first target joint pain assessment on Study Day 4 |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Lariboisière | Paris | |
France | CHU de Rouen - Hôpital Charles-Nicolle | Rouen | |
Spain | Hospital general Universitario Dr. Balmis | Alicante | |
Spain | Hospital de la Santa Creu i Sant Pau | Barcelona | |
Spain | Hospital Universitario Infanta Leonor | Madrid | |
United States | Amarillo Center of Clinical Research | Amarillo | Texas |
United States | University of Michigan | Ann Arbor | Michigan |
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Clinical Trial Site | Bothell | Washington |
United States | Great Lakes Clinical Trials | Chicago | Illinois |
United States | Omega Research | DeBary | Florida |
United States | Hillcrest Medical Research | DeLand | Florida |
United States | Altoona Research | Duncansville | Pennsylvania |
United States | Arthritis Center of North Georgia - Gainesville | Gainesville | Georgia |
United States | Arizona Arthritis & Rheumatology Associates - Glendale | Glendale | Arizona |
United States | University of Florida Health Jacksonville | Jacksonville | Florida |
United States | The Research Group of Lexington | Lexington | Kentucky |
United States | American Institute of Research | Los Angeles | California |
United States | Arizona Arthritis & Rheumatology Associates (AARA), P.C. - Mesa | Mesa | Arizona |
United States | Well Pharma Medical Research | Miami | Florida |
United States | Montana Medical Research | Missoula | Montana |
United States | IMA Clinical Research - Manhattan | New York | New York |
United States | NYU Langone | New York | New York |
United States | Clinical Trial Site | Orland Park | Illinois |
United States | Utah Health - University of Utah Hospital | Salt Lake City | Utah |
United States | TriWest Research Associates | San Diego | California |
United States | Arthritis Northwest | Spokane | Washington |
United States | Lower Country Rheumatology - Summerville | Summerville | South Carolina |
United States | Clinical Research of West Florida | Tampa | Florida |
United States | Valiance Clinical Research - Tarzana | Tarzana | California |
United States | Clinical Trial Site | Thomasville | Georgia |
Lead Sponsor | Collaborator |
---|---|
Olatec Therapeutics LLC |
United States, France, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the efficacy of dapansutrile as an acute gout flare treatment compared to placebo in reducing joint pain at 72 hours post initial loading dose of IMP | Change from baseline in the subject-assessed pain intensity score evaluated on a 100-mm visual analogue scale (VAS) in the target joint at 72 hours post initial loading dose for dapansutrile compared to placebo. The visual analog scale has anchors of 0 indicating no pain and 100 indicating the worst pain. | 72 hours | |
Secondary | Change in joint pain in the target joint at scheduled time points post initial loading dose of study drug | Change from baseline in the subject-assessed pain intensity score evaluated on a 100-mm visual analogue scale (VAS) in the target joint at specified timepoints up to Day 15 post initial loading dose of study drug. The visual analog scale has anchors of 0 indicating no pain and 100 indicating the worst pain. | 12, 24, 36, 48 and 60 hours; 8 and 15 days | |
Secondary | To assess the clinical activity of dapansutrile compared to placebo in treating signs and symptoms of an acute gout flare other than pain (tenderness, swelling, erythema, warmth, and range of motion). | Patient Global Assessment of Response to Treatment (PGART) will be completed by the subject through Day 8. The PGART is a 5-level Likert-type single item (i.e., one general question the Subject is asked to answer) about the overall perceived status of their response to treatment on a scale from "None" to "Excellent". | 4 and 8 days | |
Secondary | To assess the clinical activity of dapansutrile compared to placebo in treating signs and symptoms of an acute gout flare other than pain (tenderness, swelling, erythema, warmth, and range of motion) | Change from baseline in the Investigator-assessed Target Joint Score at scheduled assessments through Study Day 15. The Investigator-assessed Target Joint Score is a combined assessment of individual assessments for the following outcome domains: tenderness, swelling, erythema, warmth, and range of motion each with a scale of 0 through 3, with lower scoring in each domain indicating better outcomes in the respective domain. | 8 and 15 days | |
Secondary | To assess the clinical activity of dapansutrile compared to placebo in treating signs and symptoms of an acute gout flare other than pain (tenderness, swelling, erythema, warmth, and range of motion). | Investigator Global Assessment of Response to Treatment (IGART) will be completed by the Investigator through Study Day 8. The IGART is a 5-level Likert-type single item (i.e., one general question the Investigator is asked to answer) about the overall perceived status of the subject's response to treatment on a scale from "None" to "Excellent". | 4 and 8 days | |
Secondary | To further assess the clinical activity of dapansutrile compared to placebo in reducing joint pain at scheduled time points post initial loading dose of IMP. | Proportion of subjects with a response (defined as a 20%, 50%, or 70% reduction from baseline without using Rescue Medication) in the subject-assessed pain intensity score (100-mm VAS) in the target joint up to Day 15 post initial loading dose of study drug. | 48 and 72 hours; 8 and 15 days | |
Secondary | To assess the clinical activity of dapansutrile compared to placebo in treating signs and symptoms of an acute gout flare other than pain (tenderness, swelling, erythema, warmth, and range of motion). | Change from baseline in the subject-assessed Quality of Life (QoL) questionnaire Short Form Health Survey-12 version 2.0 (SF-12v2) at scheduled assessments through Study Day 15. | 15 days | |
Secondary | To further assess the clinical activity of dapansutrile compared to placebo in reducing joint pain at scheduled time points post initial loading dose of IMP. | Change from baseline in the subject-assessed pain intensity score evaluated on a 100-mm visual analogue scale (VAS) in any actively flaring non-target joint(s) up to Day 15 post initial loading dose of study drug. The visual analog scale has anchors of 0 indicating no pain and 100 indicating the worst pain. | 4, 8 and 15 days | |
Secondary | To characterize the population PK of dapansutrile and exposure-response relationship for efficacy and safety. | Blood samples will be drawn and analyzed in order to characterize the population PK of dapansutrile | up to 15 days | |
Secondary | Physical examinations | Physical examinations will be conducted to assess changes in subject health throughout the duration of the study. | Up to 15 days | |
Secondary | Vital signs | Vital signs consisting of pulse, resting blood pressure, temperature and respirations will be recorded and analyzed for changes throughout the duration of the study | Up to 15 days | |
Secondary | Electrocardiograms | Electrocardiograms will be captured and analyzed for changes throughout the duration of the study. | 15 days | |
Secondary | Safety laboratory measurements | Blood samples will be drawn and analyzed for routine chemistry blood markers, routine hematology/complete blood count and routine urinalysis will be performed throughout the duration of the study | Up to 15 days | |
Secondary | Adverse events | Adverse events will be described with respect to seriousness, intensity, relationship to treatment, action taken and outcome of the event. | Up to 36 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04228458 -
ThermRheum Version 1
|
N/A | |
Withdrawn |
NCT04976972 -
A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation
|
N/A | |
Completed |
NCT04037436 -
Functional Exercise and Nutrition Education Program for Older Adults
|
N/A | |
Completed |
NCT00069342 -
Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
|
||
Completed |
NCT02944448 -
A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee
|
Phase 2 | |
Recruiting |
NCT02498808 -
Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?
|
N/A | |
Recruiting |
NCT02777060 -
Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures
|
N/A | |
Enrolling by invitation |
NCT02487888 -
A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care
|
N/A | |
Withdrawn |
NCT02136251 -
Total Shoulder Replacement Outcomes With Autologous Bone Graft as Fixator for Glenoid Anchor Peg.
|
||
Completed |
NCT02143206 -
Modifying Exercise for the COPD Patient
|
||
Completed |
NCT01407874 -
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
|
Phase 2 | |
Completed |
NCT01285843 -
Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component
|
N/A | |
Completed |
NCT00987870 -
Safety and Efficacy of BFH772 in Psoriasis Patients
|
Phase 1/Phase 2 | |
Completed |
NCT01172327 -
Self-Directed Exercise Program for Adults With Arthritis
|
N/A | |
Completed |
NCT01184924 -
Evaluation of the Arthritis Foundation Tai Chi Program
|
N/A | |
Completed |
NCT00750984 -
A Comparison of Two Different Surgical Techniques for Total Hip Resurfacing
|
N/A | |
Active, not recruiting |
NCT00611585 -
A Safety and Efficacy Study of the Birmingham Hip Resurfacing System
|
N/A | |
Completed |
NCT00379184 -
Sensitization in Osteoarthritic Knees
|
N/A | |
Completed |
NCT00175448 -
Comparison of Physiotherapy Versus Home Exercise Following Hip Replacement Surgery
|
N/A | |
Completed |
NCT00403676 -
Nursing Consultation in Out-patient Clinics for Patients With Inflammatory Rheumatic Disease
|
N/A |